Damora Therapeutics, Inc. Ordinary Shares
DMRA
26 hedge funds and large institutions have $3.09M invested in Damora Therapeutics, Inc. Ordinary Shares in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
24% more funds holding
Funds holding: 21 → 26 (+5)
11% more capital invested
Capital invested by funds: $2.77M → $3.09M (+$314K)
0.02% more ownership
Funds ownership: 0.57% → 0.58% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$122K |
| 2 |
Jane Street
New York
|
+$18.6K |
| 3 |
STA
Summit Trail Advisors
New York
|
+$17.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$69.8K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$35.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.25K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.08K |
DMRA Hedge Fund Activity: Q1 2024 in Review
26 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2024, worth a combined $3.09M — up 11% from $2.77M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DMRA positions and 3 closed out — a net gain of 5 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $122K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $69.8K sold.
- 26 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2024, up from 21 in Q4 2023.
- Funds reported $3.09M of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2024, up 11% quarter-over-quarter.
- 8 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2024 and 3 closed out, a net change of +5 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2024 was Renaissance Technologies, an estimated $122K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2024 was Two Sigma Securities, an estimated $69.8K sold.
Based on aggregated 13F filings for Q1 2024.